SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

3/27/24 2:47:02 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OMER alert in real time by email

SC 13G/A 1 Omeros13gaisdec2023.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 12 )* OMEROS CORPORATION ----------------------------------------------------- (Name of Issuer) COMMON STOCK ----------------------------------------------------- (Title of Class of Securities) 682143102 ----------------------------------------------------- (CUSIP Number) 12/31/23 ----------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [] Rule 13d-1(c) [] Rule 13d-1(d) ---------- *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 682143102 -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON(S) I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) INGALLS & SNYDER, LLC 13-5156620 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION NEW YORK STATE -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER EACH 0 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER WITH 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 4,431,188 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,431,188 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.0% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON* IA, BD -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: OMEROS CORPORATION -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 201 ELLIOT AVENUE WEST SEATTLE, WA 98119 -------------------------------------------------------------- Item 2. (a) Name of Person Filing: INGALLS & SNYDER, LLC -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: 1325 AVENUE OF THE AMERICAS, NEW YORK, NY 10019 -------------------------------------------------------------- (c) Citizenship: USA -------------------------------------------------------------- (d) Title of Class of Securities: COMMON STOCK -------------------------------------------------------------- (e) CUSIP Number: 682143102 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Rules 240.13d-(1), or 13d-2(b) or (c), check whether the person filing is a: (a) [X] Broker or Dealer registered under Section 15 of the Act, (15 U.S.C 78o) (b) [ ] Bank as defined in Section 3(a)(6) of the Act, (15 U.S.C 78c) (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act, (15 U.S.C 78c) (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8) (e) [X] Investment Adviser in accordance with Section 240.13d-1(b)(1)(ii)(E) (f) [ ] Employee Benefit Plan or endowment fund in accordance to Section 240.13d-1(b)(ii)(F) (g) [ ] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G) (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C 1813) (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C 80a-3) (j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J) Item 4. Ownership. (a) Amount beneficially owned: 4,431,188 (b) Percent of class: 7.0% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote 0 (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of 4,431,188 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following []. INAPPLICABLE Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Ingalls & Snyder, LLC ("I&S") is a registered broker dealer and a registered investment advisor. Shares reported under shared dispositive power include shares held in accounts managed under investment advisory contracts. Share count assumes conversion of 641,000 and conversion of $620,000 Omeros 5.25% due 2/15/26. Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. INAPPLICABLE Item 8. Identification and Classification of Members of the Group. INAPPLICABLE Item 9. Notice of Dissolution of Group. INAPPLICABLE Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: 03/22/24 BY: /s/ Thomas O. Boucher ---------------------------------- (Signature)* Thomas O. Boucher Managing Director

Get the next $OMER alert in real time by email

Recent Analyst Ratings for

$OMER

Date	Price Target	Rating	Analyst
6/10/2025	$9.00	Buy	H.C. Wainwright
12/23/2024	$36.00	Buy	D. Boral Capital
11/14/2024	$9.00	Buy	Rodman & Renshaw
12/8/2022	$12.00 → $2.00	Buy → Neutral	UBS
11/8/2022	$8.00 → $3.00	Neutral → Underperform	BofA Securities
6/8/2022	$12.00 → $4.00	Buy → Neutral	BofA Securities
10/19/2021	$19.00 → $12.00	Buy	HC Wainwright & Co.
10/8/2021		Neutral → Underweight	JP Morgan

More analyst ratings

SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

3/27/24 2:47:02 PM ET

$OMER

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OMER alert in real time by email

Recent Analyst Ratings for

$OMER

Date	Price Target	Rating	Analyst
6/10/2025	$9.00	Buy	H.C. Wainwright
12/23/2024	$36.00	Buy	D. Boral Capital
11/14/2024	$9.00	Buy	Rodman & Renshaw
12/8/2022	$12.00 → $2.00	Buy → Neutral	UBS
11/8/2022	$8.00 → $3.00	Neutral → Underperform	BofA Securities
6/8/2022	$12.00 → $4.00	Buy → Neutral	BofA Securities
10/19/2021	$19.00 → $12.00	Buy	HC Wainwright & Co.
10/8/2021		Neutral → Underweight	JP Morgan

More analyst ratings

SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$OMER

SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$OMER

$OMER
SEC Filings

SEC Form 10-Q filed by Omeros Corporation

Omeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEF 14A filed by Omeros Corporation

$OMER
Analyst Ratings

H.C. Wainwright initiated coverage on Omeros with a new price target

D. Boral Capital initiated coverage on Omeros with a new price target

Rodman & Renshaw initiated coverage on Omeros with a new price target

$OMER
Insider Trading

Director Cable Thomas J. exercised 7,500 shares at a strike of $10.84 and sold $87,039 worth of shares (7,500 units at $11.61) as part of a pre-agreed trading plan (SEC Form 4)

Chairman, CEO & President Demopulos Gregory A Md exercised 400,000 shares at a strike of $10.27 and covered exercise/tax liability with 357,678 shares, increasing direct ownership by 3% to 1,469,308 units (SEC Form 4)

VP, Finance & CAO Borges David J. sold $750,915 worth of shares (60,000 units at $12.52) and exercised 30,000 shares at a strike of $3.06, closing all direct ownership in the company (SEC Form 4)

$OMER
Press Releases

Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

$OMER
Insider Purchases

Demopulos Gregory A Md bought $25,200 worth of shares (15,000 units at $1.68) (SEC Form 4)

Demopulos Peter A Md bought $15,300 worth of shares (10,000 units at $1.53), increasing direct ownership by 5% to 208,516 units (SEC Form 4)

$OMER
Leadership Updates

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

$OMER
Financials

Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

$OMER
Large Ownership Changes